Cargando…
Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
Background and Objectives; Triple-negative breast cancer (TNBC) is associated with poor patient prognosis because of its multiple molecular features. Thus, more effective treatment for TNBC is urgently needed. This study determined the possible involvement of ERK1/2 activation in cisplatin-induced c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025504/ https://www.ncbi.nlm.nih.gov/pubmed/35454385 http://dx.doi.org/10.3390/medicina58040547 |
_version_ | 1784690888663891968 |
---|---|
author | Ko, Hyemi Lee, Myungsun Cha, Eunyoung Sul, Jiyoung Park, Junbeom Lee, Jinsun |
author_facet | Ko, Hyemi Lee, Myungsun Cha, Eunyoung Sul, Jiyoung Park, Junbeom Lee, Jinsun |
author_sort | Ko, Hyemi |
collection | PubMed |
description | Background and Objectives; Triple-negative breast cancer (TNBC) is associated with poor patient prognosis because of its multiple molecular features. Thus, more effective treatment for TNBC is urgently needed. This study determined the possible involvement of ERK1/2 activation in cisplatin-induced cytotoxicity in TNBC by providing additional eribulin treatment. Materials and Methods; We investigated cell viability and apoptosis caused by eribulin, cisplatin, or co-treatment in HCC38, MDA-MB-231, and SKBR3 human breast cancer cells. Results; Cisplatin significantly lowered cell viability and caused high apoptotic cell death in all breast cancer cell lines. The viability of TNBC cells was significantly lower in the group co-treated with cisplatin and eribulin than in the cisplatin-only treatment group. Additional eribulin treatment significantly enhanced PARP cleavage and caspase-3 activity in cisplatin-treated TNBC cells. Moreover, cisplatin treatment activated ERK1/2 in all breast cancer cell lines. The cisplatin and eribulin combination synergistically activated ERK1/2 in TNBC cells compared with the cisplatin-only treatment. Administration of the ERK1/2 inhibitor PD98059 increased the viability of TNBC cells treated with cisplatin plus eribulin. Conclusions; Eribulin could synergize the cytotoxic and apoptotic activities of cisplatin and increase ERK1/2 activation, thus enhancing anti-cancer effects against TNBC cells. |
format | Online Article Text |
id | pubmed-9025504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90255042022-04-23 Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation Ko, Hyemi Lee, Myungsun Cha, Eunyoung Sul, Jiyoung Park, Junbeom Lee, Jinsun Medicina (Kaunas) Article Background and Objectives; Triple-negative breast cancer (TNBC) is associated with poor patient prognosis because of its multiple molecular features. Thus, more effective treatment for TNBC is urgently needed. This study determined the possible involvement of ERK1/2 activation in cisplatin-induced cytotoxicity in TNBC by providing additional eribulin treatment. Materials and Methods; We investigated cell viability and apoptosis caused by eribulin, cisplatin, or co-treatment in HCC38, MDA-MB-231, and SKBR3 human breast cancer cells. Results; Cisplatin significantly lowered cell viability and caused high apoptotic cell death in all breast cancer cell lines. The viability of TNBC cells was significantly lower in the group co-treated with cisplatin and eribulin than in the cisplatin-only treatment group. Additional eribulin treatment significantly enhanced PARP cleavage and caspase-3 activity in cisplatin-treated TNBC cells. Moreover, cisplatin treatment activated ERK1/2 in all breast cancer cell lines. The cisplatin and eribulin combination synergistically activated ERK1/2 in TNBC cells compared with the cisplatin-only treatment. Administration of the ERK1/2 inhibitor PD98059 increased the viability of TNBC cells treated with cisplatin plus eribulin. Conclusions; Eribulin could synergize the cytotoxic and apoptotic activities of cisplatin and increase ERK1/2 activation, thus enhancing anti-cancer effects against TNBC cells. MDPI 2022-04-15 /pmc/articles/PMC9025504/ /pubmed/35454385 http://dx.doi.org/10.3390/medicina58040547 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ko, Hyemi Lee, Myungsun Cha, Eunyoung Sul, Jiyoung Park, Junbeom Lee, Jinsun Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation |
title | Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation |
title_full | Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation |
title_fullStr | Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation |
title_full_unstemmed | Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation |
title_short | Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation |
title_sort | eribulin mesylate improves cisplatin-induced cytotoxicity of triple-negative breast cancer by extracellular signal-regulated kinase 1/2 activation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025504/ https://www.ncbi.nlm.nih.gov/pubmed/35454385 http://dx.doi.org/10.3390/medicina58040547 |
work_keys_str_mv | AT kohyemi eribulinmesylateimprovescisplatininducedcytotoxicityoftriplenegativebreastcancerbyextracellularsignalregulatedkinase12activation AT leemyungsun eribulinmesylateimprovescisplatininducedcytotoxicityoftriplenegativebreastcancerbyextracellularsignalregulatedkinase12activation AT chaeunyoung eribulinmesylateimprovescisplatininducedcytotoxicityoftriplenegativebreastcancerbyextracellularsignalregulatedkinase12activation AT suljiyoung eribulinmesylateimprovescisplatininducedcytotoxicityoftriplenegativebreastcancerbyextracellularsignalregulatedkinase12activation AT parkjunbeom eribulinmesylateimprovescisplatininducedcytotoxicityoftriplenegativebreastcancerbyextracellularsignalregulatedkinase12activation AT leejinsun eribulinmesylateimprovescisplatininducedcytotoxicityoftriplenegativebreastcancerbyextracellularsignalregulatedkinase12activation |